The optimal management of venous thromboembolism (VTE) has long been a clinical challenge.[1] Unprovoked VTE may be the earliest sign of cancer, and this association has been
long recognized.[2]
[3] Indeed, up to 10% of patients with unprovoked VTE will receive a diagnosis of cancer
in the year after their diagnosis of VTE.[4]
Therefore, clinicians and scientists have long advocated systematic testing of asymptomatic
individuals (i.e. screening) for pre-clinical occult malignancy. Subjecting patients
to an extensive diagnostic workup could alter their clinical course: an earlier cancer
diagnosis might potentially lead to earlier and more effective treatment and would
also affect anticoagulation choice. However, routine screening for occult cancer after
unprovoked VTE is not supported by current evidence. The Screening for Occult Malignancy
in Patients with Idiopathic Venous Thromboembolism (SOME) trial randomized patients
with unprovoked VTE to a limited screening strategy involving standard age- and sex-specific
screening or to an extensive strategy that added computed tomography of the abdomen
and pelvis.[5] Among 854 patients, the primary outcome of the study (the number of cancers ‘missed’
at the initial screening but diagnosed by the end of the 1-year follow-up period)
was 0.93% in the limited screening group and 1.18% in the extensive screening group.
Since a sub-group of high-risk patients could potentially benefit from a more extensive
occult cancer screening strategy, investigators have developed risk scores that might
provide a basis for effective screening and preventive strategies. For example, Jara-Palomares
et al identified 6 independent predictors (RIETE score) assessed at the time of VTE
presentation of occult cancer in a 24-month follow-up period: male sex, age > 70 years,
chronic lung disease, anaemia (haemoglobin levels < 13 g/dL for men and < 12 g/dL
for women), elevated platelet count (≥ 350,000 × 1,000/mm3), prior VTE and recent surgery.[6] For each patient, the score assigned 2 points each for the presence of age > 70
years and anaemia, and 1 point each for the presence of male sex, chronic lung disease
and raised platelet count; and 2 negative points for the presence of recent surgery.
Patients with a total score of ≤ 2 were assigned to the low-risk category, and those
with a total score of ≥ 3 points to the high-risk category. Six percent (95% confidence
interval [CI], 5.1–6.6%) of the low-risk patients versus 12% (95% CI, 10.4–13.5%)
of the high-risk patients were diagnosed with cancer during follow-up.[6] Ihaddadene et al performed a posthoc analysis of the SOME trial and found that age ≥ 60
years (hazard ratio [HR], 3.1; 95% CI, 1.4–6.9; p = 0.005), previous provoked VTE (HR, 3.2; 95% CI, 1.2–8.62; p = 0.022) and current smoker status (HR, 2.8; 95% CI, 1.2–6.3; p = 0.014) were associated with occult cancer detection (SOME score).[7]
To show that a prognostic model is valuable, it is not sufficient to show that it
successfully predicts outcome in the initial development data. We need evidence that
the model performs well for other groups of patients.[8] It is important to check the proportion of patients classified by the rule in the
different prognostic groups, as well as its accuracy and calibration. The validation
cohort should represent an unselected group of patients with a wide spectrum of disease
severity, and the predictors for the rule should be collected blinded from the final
outcome.
In the previous issue of Thrombosis and Haemostasis, Kraaijpoel and a team of renowned clinical scientists performed a posthoc analysis
of the Hokusai-VTE trial to evaluate the performance of the RIETE and SOME scores
for the occurrence of subsequent occult cancer in patients with acute VTE.[9] A total of 8,032 patients were included in the analysis. The incidence of occult
cancer was 1.8% in patients with unprovoked VTE (5,359 patients, 67%), and 2.1% in
those with provoked VTE (2,673 patients, 33%). The RIETE score classified 19% of patients
as having a ‘high risk’ of occult cancer and the SOME score 16%. In patients classified
as ‘high risk’, the cumulative incidence of cancer diagnosis during follow-up was
2.9% (95% CI, 2.1–3.9%) for the RIETE score and 2.7% (95% CI, 1.9–3.7%) for the SOME
score, corresponding to HRs of 1.8 (95% CI, 1.3–2.5) and 1.5 (95% CI, 1.04–2.2), respectively.
The C-statistics of the RIETE and SOME scores were 0.62 (95% CI, 0.57–0.66) and 0.59 (95%
CI, 0.55–0.62), respectively.
Various factors might explain the relatively poor predictive capability of the two
models assessed in this study. The models' predictions might not be reproducible because
of deficiencies in the modelling methods used in the study to derive the model. Poor
performance could also arise from differences between the setting of patients in the
new and derivation samples. Randomized controlled trials (RCTs) are currently the
best approach to evaluate the effectiveness of therapies while accounting for the
effects of unmeasured confounders and selection bias by indication. However, there
is reasonable concern about inadequate representativeness of RCTs. In a recent study
by the RIETE registry on the real-life use of direct oral anticoagulants in patients
with VTE, 19% met at least one exclusion criterion for the trials where the indication
was established.[10] The higher incidence of occult cancer in the sub-group of patients with provoked
VTE (compared with the sub-group of patients with unprovoked VTE) might suggest that
a non-representative group of patients were enrolled in the Hokusai-VTE trial.
Based on the results of the Kraaijpoel et al study, the value of these scores is questionable.
Other factors such as presence of extensive VTE (including bilateral deep vein thrombosis)
have recently shown promise,[11] whereas more traditional cancer risk factors such as longstanding history of smoking,
alcohol overuse, history of radiation and family history of early cancer may warrant
further assessment. In addition, cancer-specific biomarkers might improve the discriminative
performance of these risk scores and require further validation (ClinicalTrials.gov;
NCT02739867). The final step would involve assessing the impact of its use on practice
patterns, outcomes of care and costs.[12] Until these score are available, a limited screening strategy involving standard
age- and sex-appropriate screening is advisable.
